Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside
I'm PortAI, I can summarize articles.
Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Aldeyra Therapeutics with a $10.00 price target. Confidence in Reproxalap’s approval and financial upside, including a potential $200 million co-exclusive license agreement with AbbVie, underpins this rating. Despite the PDUFA target action date extension to March 2026, no additional FDA issues were raised. Caufield, a 5-star analyst, highlights Aldeyra’s procedural progress and differentiated product profile.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments